2LEBOVITZ H, DDE J F, PATWARDHAN R, et al. Rosiglitazone monotherapy is effective in patients with type 2diabetes[ J]. J Clin Endocfinol Metab, 2001, 86 : 280 - 288.
3MATTEWS D R, HOSKER J P, RUDENSKi A S, et al. Homeostasis model assessment : Insulin resistance and beta - cell function from fasting plasma glucose and insulin concentration in man [ J ]. Diabetologia, 1985, 28 : 412 -419.
4YAMAGISHI S, TAKEUCHI M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR -gamma- inducing property[J]. Med Hypotheses, 2005, 64 ( 3 ) :476 - 478.
5KURTZ T W, PRAVENEC M. Antidiabetic mechanisms of angiotensin - converting enzyme inhibitors and angiotensin Ⅱ receptor antagonists : beyond the renin - angiotensin system [ J ]. J Hypertens, 2004, 22(12) : 2 253 -2 261.
6DOGGRELL S A. Telmisartan - killing two birds with one stone [J]. Expert Opin Pharmacother, 2004, 5( 11 ): 2 397-2 400.
7DE GASPARO M, LEVENS N. Does blockade of angiotensin Ⅱreceptors offer clinical benefits over inhibition of angiotensin - converting enzyme? [J]. Pharmacol Toxicol, 1998, 82:257-271.
8STRUTHERS A D. Aldosterone escape during angiolensin - converting enzyme inhibitor therapy in chronic heart failure[J]. J Card Fail, 1996, 2:47 -54.
9METIN G, ATUKEREN P, ALTURFAN A A,et al. Lipid peroxidation, erythrocyte superoxide-dismutase activity and trace metals in young male foot-ballers[J]. Yonsei Med J,2003 ,44:979-986.
10CHOLEWINSKI W, STEFANIAK B. PONIATOWICZ-FRASUNEK E, et al. Reduction of the LVEF measured with gSPECT after 1-3 hours after physical exercise in CAD[J]. Nuklearmedizin, 2004 , 43 :150 -157.
